"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
| Descriptor ID |
D007980
|
| MeSH Number(s) |
D02.092.311.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500
|
| Concept/Terms |
Levodopa- Levodopa
- L-Dopa
- L Dopa
- 3-Hydroxy-L-tyrosine
- 3 Hydroxy L tyrosine
- L-3,4-Dihydroxyphenylalanine
- L 3,4 Dihydroxyphenylalanine
|
Below are MeSH descriptors whose meaning is more general than "Levodopa".
Below are MeSH descriptors whose meaning is more specific than "Levodopa".
This graph shows the total number of publications written about "Levodopa" by people in this website by year, and whether "Levodopa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 14 | 10 | 24 |
| 2018 | 11 | 7 | 18 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Levodopa" by people in Profiles.
-
Severe Dyskinesia After Administration of SARS-CoV2 mRNA Vaccine in Parkinson's Disease. Mov Disord. 2021 10; 36(10):2219.
-
Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19. BMJ Case Rep. 2021 Mar 02; 14(3).
-
COVID-19 and Parkinson's Disease: What Do We Know So Far? J Parkinsons Dis. 2021; 11(2):445-454.
-
[Amantadine in the treatment of Parkinson's disease. New opportunities in the context of COVID-19]. Zh Nevrol Psikhiatr Im S S Korsakova. 2021; 121(4):101-106.
-
Outcome of Parkinson's Disease Patients Affected by COVID-19. Mov Disord. 2020 06; 35(6):905-908.
-
What can Parkinson's disease teach us about COVID-19? Neurol Neurochir Pol. 2020; 54(2):204-206.
-
Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD. Neurobiol Aging. 2019 09; 81:177-189.
-
The influence of postural deformities on neck function and pain in patients with Parkinson's disease. NeuroRehabilitation. 2019; 44(1):79-84.
-
Neuroleptic malignant-like syndrome causing thrombocytopaenia: a rare association. BMJ Case Rep. 2018 Dec 03; 11(1).
-
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol. 2018 12; 84(6):797-811.